Foghorn Therapeutics (FHTX) Common Equity (2019 - 2026)

Foghorn Therapeutics' Common Equity history runs 8 years deep, the most recent figure standing at -$76.4 million for Q1 2026.

• In Q1 2026, Common Equity fell 23.93% year-over-year to -$76.4 million; the TTM figure through Mar 2026 stood at -$76.4 million (down 23.93% YoY), while the FY2025 annual figure was -$108.5 million, down 138.31% from the prior year.
• Common Equity for Q1 2026 stood at -$76.4 million, up from -$108.5 million in the prior quarter.
• The five-year high for Common Equity was $72.4 million in Q1 2022, with the low at -$108.5 million in Q4 2025.
• The 5-year median for Common Equity is -$49.3 million (2023), against an average of -$39.0 million.
• The sharpest annual moves came in 2023 and 2024: Common Equity plunged 69019.64% in 2023, then jumped 70.98% in 2024.
• Foghorn Therapeutics' Common Equity stood at $112000.0 in 2022, then slumped by 69019.64% to -$77.2 million in 2023, then jumped by 41.02% to -$45.5 million in 2024, then tumbled by 138.31% to -$108.5 million in 2025, then gained by 29.58% to -$76.4 million in 2026.
• Business Quant data shows FHTX's Common Equity at -$76.4 million in Q1 2026, -$108.5 million in Q4 2025, and -$89.7 million in Q3 2025.